Should patients be given an initial low test dose of sildenafil?
- PMID: 10915029
- DOI: 10.2165/00002018-200023010-00001
Should patients be given an initial low test dose of sildenafil?
Abstract
Sildenafil is highly effective for treating erectile dysfunction (ED). However, its use has been associated with serious adverse events including myocardial infarctions and strokes, and 130 verifiable plus 112 unverified deaths reported to the US Food and Drug Administration during the 8 months after sildenafil was introduced in the US, and 522 reported deaths during the 13.5 months after its introduction. Moreover, some events have occurred in men taking their first dose of the agent, suggesting that sildenafil, like some drugs that affect blood pressure, may provoke a first-dose reaction. This possibility warrants extra caution to be used when initiating treatment with sildenafil. Such caution is not currently provided by the current dosage guidelines that, for example, recommend the use of sildenafil 50 mg initially for most men between the ages of 18 and 65 years, despite wide differences in bodyweight, age, drug metabolism, health status and usage of other medications. It can be difficult to identify the patient who may be unusually sensitive to the effects of sildenafil. Exercise stress tests have been recommended, but serious adverse events have occurred in men with normal stress tests following the ingestion of sildenafil. Blood pressure monitoring following sildenafil administration will not prevent a serious adverse drug event already in progress. This article discusses the advantages and disadvantages of initiating treatment with a low test dose of sildenafil, performed at home or in the doctor's office. The advantages of this approach include: (i) identifying patients who are highly sensitive to the effects of sildenafil and who may need no higher dose; (ii) minimising adverse effects such as flushing and dizziness that often frighten patients and may affect adherence; (iii) avoidance of major adverse events; and (iv) reassuring patients with ED who remain wary about trying sildenafil therapy.
Similar articles
-
An open-label, multicentre, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in men naïve to phosphodiesterase 5 inhibitor therapy.BJU Int. 2005 Dec;96(9):1323-32. doi: 10.1111/j.1464-410X.2005.05892.x. BJU Int. 2005. PMID: 16287454 Clinical Trial.
-
Sildenafil citrate for erectile dysfunction in men receiving multiple antihypertensive agents: a randomized controlled trial.Am J Hypertens. 2004 Dec;17(12 Pt 1):1135-42. doi: 10.1016/j.amjhyper.2004.07.004. Am J Hypertens. 2004. PMID: 15607620 Clinical Trial.
-
Cardiovascular safety of sildenafil citrate (Viagra): an updated perspective.Urology. 2006 Sep;68(3 Suppl):47-60. doi: 10.1016/j.urology.2006.05.047. Urology. 2006. PMID: 17011375 Review.
-
Sildenafil: a review of its use in erectile dysfunction.Drugs. 1999 Jun;57(6):967-89. doi: 10.2165/00003495-199957060-00015. Drugs. 1999. PMID: 10400408 Review.
-
Efficacy, safety and patient acceptance of sildenafil citrate as treatment for erectile dysfunction.J Urol. 2000 Oct;164(4):1192-6. J Urol. 2000. PMID: 10992364
Cited by
-
A risk-benefit assessment of sildenafil in the treatment of erectile dysfunction.Drug Saf. 2001;24(4):255-65. doi: 10.2165/00002018-200124040-00003. Drug Saf. 2001. PMID: 11330655 Review.
-
A Systematic Review of Sildenafil Mortality Through the Years.Cureus. 2022 Dec 4;14(12):e32179. doi: 10.7759/cureus.32179. eCollection 2022 Dec. Cureus. 2022. PMID: 36474651 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources